Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 46

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

558

Figures (1-3)

Tables (1-4)

Sum=701

Publishing Process of This Article

Item

Count

Browse

Download

Sum=112

Dec 14, 2024 (publication date) through Jan 4, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Dec 14, 2024; 30(46): 4904-4913
Published online Dec 14, 2024. doi: 10.3748/wjg.v30.i46.4904

Full Size Figure Download Figure

Figure 1 Patient selection.

Citation: Liu Chen Kiow J, Hoang T, Bedi HK, Majdzadeh Ardekani Z, Rosenfeld D, Reise-Filteau M, Bressler B, Leung Y, Rosenfeld G. Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease. World J Gastroenterol 2024; 30(46): 4904-4913
URL: https://www.wjgnet.com/1007-9327/full/v30/i46/4904.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i46.4904